Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Takeda acquiring Nimbus Therapeutics subsid for US$4 Billion

<< Previous

Bullboard Posts

Next >>

Post by Noteableon Dec 13, 2022 12:19pm

400 Views

Post# 35168732

Takeda acquiring Nimbus Therapeutics subsid for US$4 Billion

December 13, 2022 - Takeda is paying $4 billion upfront to buy Nimbus’ wholly owned subsidiary, Nimbus Lakshmi, to obtain NDI-034858, a TYK2 inhibitor to be applied in psoriasis. TYK2 is part of the JAK family.

"By persuading Takeda that NDI-034858 can come from behind to make a dent on the market, Nimbus has continued a winning streak and business model that has allowed it to offload drug candidates while keeping its discovery engine in a high gear."

https://www.fiercebiotech.com/biotech/takeda-bets-4b-upfront-nimbus-phase-3-ready-prospect-challenge-bristol-myers-psoriasis

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing